CI and Patent News: 13/11/2010


1) Forest Laboratories, Inc today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

2) One more decision from Brazil supreme court on Pipeline system (IP Tango) (INPI)

3) Ablynx receives further milestone payments from Boehringer. Ablynx and Boehringer have entered in strategic alliance for developing Nanobody therapeutics in Oncology and many therapeutic areas (link)

4) Pozen announced approval of VIMOVO (naproxen/ esomeprazole magnesium) and would receive milestone payment from Astrazeneca (link). Note: Pozen already had successfully marketed combination of Sumatriptan/Naproxen combination in collaboration with GSK.

5) Germany will soon levy over $2bn worth of price cuts on drug makers launching new products (WSJ) (Ills, Pills)

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s